TY - JOUR T1 - Respiratory healthcare professionals’ views on long-term recommendations of interventions to prevent acute respiratory illnesses after the COVID-19 pandemic JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00114-2022 SP - 00114-2022 AU - Karin Yaacoby-Bianu AU - Galit Livnat AU - James D. Chalmers AU - Michal Shteinberg Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/07/22/23120541.00114-2022.abstract N2 - During the Coronavirus-19 (COVID-19) pandemic, health care authorities adopted measures to reduce the spread of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). These were lockdowns, social distancing, using facemasks and increased hand sanitising. People with chronic respiratory conditions were encouraged to comply with these measures [1]. Furthermore, it was suggested that nebulisation may facilitate the transmission of COVID-19 [2, 3], therefore respiratory societies recommended using inhalers where appropriate [2, 4, 5]. During 2020, significant reductions in the incidences of acute respiratory illnesses including influenza [6–8] and acute exacerbations of chronic airway diseases [9–11] were reported. These reductions may be attributed to the effects of the measures implemented for COVID-19 prevention. It is undetermined whether these measures should be extended to prevent acute respiratory illnesses, in future times when the threat of COVID-19 is lifted.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: KY reports grants from Vertex pharmaceuticals, grants from Gilead, outside the submitted work; GL reports grants and non-financial support from Vertex Pharmaceuticals, grants from Enanta Pharmaceuticals, grants from MedImmune, grants from DoseNTRX, outside the submitted work; JC reports grants and personal fees from Astrazeneca, grants and personal fees from Boehringer-Ingelheim, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, grants from Gilead Science, grants and personal fees from Novartis, grants and personal fees from Insmed, personal fees from Zambon, personal fees from Janssen, personal fees from Grifols, outside the submitted work; MS reports grants, personal fees and non-financial support from GSKÐ grants and personal fees from Novartis, personal fees from Bohringer- Ingelheim, personal fees from Astra Zeneca, personal fees from Kamada, personal fees from Vertex pharmaceuticals, personal fees from Teva, non-financial support from Actelion, grants, personal fees and non-financial support from GSK, grants from Novartis, non-financial support from Rafa, personal fees from Zambon, personal fees from Bonus therapeutics, outside the submitted work. ER -